Generic Name and Formulations:
Fluorescein (as sodium) 100mg/mL (10%); soln for IV inj; preservative-free.
Alcon Laboratories, Inc.
Indications for FLUORESCITE:
Diagnostic angiography or angioscopy of the retina and iris vasculature.
Give by IV inj rapidly into the antecubital vein (normally 1mL/sec). 500mg (5mL). Highly sensitive imaging system (eg, scanning laser ophthalmoscope): reduce dose to 2mL.
Give by IV inj rapidly into the antecubital vein (normally 1mL/sec). 7.7mg/kg; max 500mg (5mL).
History of allergy. Bronchial asthma. Avoid extravasation; severe local tissue damage can result. Pregnancy. Nursing mothers: discontinue for ≥4 days after inj (pump and discard the milk during this period).
Skin and urine discoloration, nausea, vomiting, GI distress, hypersensitivity reactions, headache, thrombophlebitis; rare: cardiopulmonary reactions, convulsions, syncope.
Single use vial (5mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib